AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study

Karachaliou, N; Morales-Espinosa, D; Vila, MAM; Garde, J; Baron, F; Cobo, M; Lopez-Vivanco, G; Majem, M; Sanchez, JM; Viteri, S; Mayo, C; Garcia, M; Rosell, R

JOURNAL OF THORACIC ONCOLOGY, 2017; 12 (1): S1074

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索